Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria

Experimental Hematology

Volumn 39, Issue 7, 2011, Pages 784-794

  Wang, Yongming ^a   Langer, Nathaniel B ^b   Shaw, George C ^b   Yang, Guang ^b   Li, Liangtao ^c   Kaplan, Jerry ^c   Paw, Barry H ^b   Bloomer, Joseph R ^a  

^a University of Alabama at Birmingham   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; COMPLEMENTARY DNA; FERROCHELATASE; HEME; IRON; MESSENGER RNA; PROTOPORPHYRIN;

ADOLESCENT; ADULT; AGED; ALAS2 GENE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STABILITY; ERYTHROPOIETIC PROTOPORPHYRIA; EXON; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENETIC DISORDER; HETEROZYGOTE; HUMAN; HUMAN CELL; INTRON; LYMPHOBLAST; MALE; MITOCHONDRION; MITOFERRIN 1 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SPLICING; RNA TRANSCRIPTION; STOP CODON;

5-AMINOLEVULINATE SYNTHETASE; ADOLESCENT; ADULT; AGED; ANIMALS; BASE SEQUENCE; CATION TRANSPORT PROTEINS; CERCOPITHECUS AETHIOPS; CHILD; COS CELLS; EMBRYO, NONMAMMALIAN; FEMALE; FERROCHELATASE; GENE EXPRESSION; GENETIC COMPLEMENTATION TEST; HUMANS; K562 CELLS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; PROTOPORPHYRIA, ERYTHROPOIETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; XENOPUS; YEASTS; YOUNG ADULT;

DANIO RERIO;

EID: 79960592056     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.05.003     Document Type: Article

References (51)

1. Lecha M., Puy H., Deybach J.C. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19-29.
2. Poh-Fitzpatrick M.B. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatology 1986, 3:148-157.
3. Timonen K., Kariniem A., Niemi K., Teppo A., Tenlvunen R., Kauppinen R. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol 2000, 43:489-497.
4. Bloomer J.R., Phillips M.J., Davidson D.L., Klatskin G. Hepatic disease in erythropoietic protoporphyria. Am J Med 1975, 58:869-882.
5. Doss M.O., Frank M. Hepatobiliary implications and complications in protoporphyria, a 20 year study. Clin Biochem 1989, 22:223-229.
6. Avner D.L., Lee R.G., Berenson M.M. Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver. J Clin Invest 1981, 67:385-394.
7. Rademakers L.H., Cleton M.I., Kooijman C., baart de la Faille H., van Hattum J. Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment. Hepatology 1990, 11:449-457.
8. Meerman L., Koopen N.R., Bloks B., et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999, 117:696-705.
9. Komatsu H., Sajima Y., Imamura K., et al. An ultrastructural study of the liver in erythropoietic protoporphyria. Med Electron Microsc 2000, 33:32-38.
10. McGuire B.M., Bonkovsky H.L., Carithers R.L., et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transplant 2005, 11:1590-1596.
11. Bottomley S.S., Tanaka M., Everet M.A. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med 1975, 86:126-131.
12. Bonkovsky H.L., Bloomer J.R., Ebert P.S., Mahoney M.J. Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest 1975, 56:1139-1148.
13. Scholnick P., Marver H.S., Schmid R. Erythropoietic protoporphyria: evidence for multiple sites of excess protoporphyrin formation. J Clin Invest 1971, 50:203-207.
14. Poh-Fitzpatrick M.B. Protoporphyrin metabolic balance in human protoporphyria. Gastroenterology 1985, 88:1239-1242.
15. Dailey H.A., Dailey T.A., Wu C.K., Medlock A.E., Wang K.F. Ferrochelatase at the millennium: structures, mechanisms and [2Fe-2S] clusters. Cell Mol Life Sci 2000, 57:1909-1926.
16. Wu C.K., Dailey H.A., Rese J.P., Burden A.M., Sellers V.A., Wang B.C. The 2A structure of human ferrochelatase, the terminal enzyme of heme biosynthesis. Nat Struct Biol 2001, 18:156-160.
17. Nakahashi Y., Taketani S., Okuda M., Inoue K., Tokunaga R. Molecular cloning and sequence analysis of cDNA encoding human ferrochelatase. Biochem Biophys Res Comm 1990, 173:748-755.
18. Taketani S., Inazawa J., Nakahashi Y., Abe T., Tokunaga R. Structure of the human ferrochelatase gene. Eur J Biochem 1992, 205:217-222.
19. Wang X., Poh-Fitzpatrick M., Taketani S., Chen T., Piomelli S. Screening for ferrochelatase mutations: molecular heterogeneity of erythropoietic protoporphyria. Biochem Biophys Acta 1994, 1225:187-190.
20. Rufenacht U.B., Gouya L., Schneider-Yin X., et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 1998, 62:1341-1352.
21. Sellers V.M., Dailey T.A., Dailey H.A. Examination of ferrochelatase mutations that cause erythropoietic protoporphyria. Blood 1998, 91:3980-3985.
22. Gouya L., Puy H., Lamoril J., et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 1999, 93:2105-2110.
23. Gouya L., Puy H., Robreau A., et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002, 30:27-28.
24. Risheg H., Chen F.P., Bloomer J.R. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab 2003, 80:196-206.
25. Whatley S.D., Mason N.G., Holme S.A., Anstey A.V., Elder G.H., Badminton M.N. Gene dosage analysis identifies large deletions of FECH gene in 10% of families with erythropoietic protoporphyria. J Invest Dermatol 2007, 127:2790-2794.
26. Whatley S.D., Ducamp S., Gouya L., et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause x-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008, 83:408-414.
27. Taketani S., Kakimoto K., Veta H., Masaki R., Furukawa T. Involvement of ABC7 in the biosynthesis of heme in erythroid cells: interaction of ABC7 with ferrochelatase. Blood 2003, 101:3274-3280.
28. Han A.P., Fleming M.D., Chen J.J. Heme-regulated eIF2-kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and B-thalassemia. J Clin Invest 2005, 115:1562-1570.
29. Cooperman S.S., Meyroen-Holtz E.G., Olivierre-Wilson H., Ghosh M.C., McConnell J.P., Rouault T.A. Microcytic anemia, erythropoietic protoporphyria and neurodegeration in mice with targeted deletion of iron-regulatory protein 2. Blood 2005, 106:1084-1091.
30. Galy B., Ferring D., Minana B., et al. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood 2005, 106:2580-2589. Epub 2005 Jun 14.
31. Shaw G.C., Cope J.J., Li L., et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006, 440:96-100.
32. Chen W., Dailey H.A., Paw B.H. Ferrochelatase forms an oligomeric complex with mitoferrin1 and Abcb10 for erythroid heme biosynthesis. Blood 2010, 116:628-630.
33. Bloomer J., Bruzzone C., Zhu L., Scarlett Y., Magness S., Brenner D. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest 1998, 102:107-114.
34. Chen F.P., Risheg H., Liu Y., Bloomer J.R. Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease. Cell Mol Biol 2002, 48:83-89.
35. Li L., Kaplan J. A mitochondrial-vacuolar signaling pathway in yeast that affects iron and copper metabolism. J Biol Chem 2004, 279:33653-33661.
36. Chen W., Paradkar P.N., Li L., et al. Abcb10 physically interacts with mitoferrin1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci U S A 2009, 106:16263-16268.
37. Yang G., Huang S.C., Wu J.Y., Benz E.J. Regulated Fox-2 isoform expression mediates protein 4.1R splicing during erythroid differentiation. Blood 2008, 111:392-401.
38. Wohlrab H. Transport proteins (carriers) of mitochondria. IUBMB Life 2009, 61:40-46.
39. Paradkar P.N., Zumbrennen K.B., Paw B.H., Ward D.M., Kaplan J. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol 2009, 29:1007-1016.
40. Holbrook J.A., Neu-Yilik G., Hentze M.W., Kulozik A. Nonsense-mediated decay approaches the clinic. Nat Genet 2004, 36:801-808.
41. Taketani S., Adachi Y., Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur J Biochem 2000, 267:4685-4692.
42. Crooks D.R., Ghosh M.C., Haller R.G., Tong W.H., Rouault T.A. Post-translational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood 2010, 115:860-869.
43. Wingert R.A., Galloway J.L., Barut B., et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 2005, 436:1035-1039.
44. Buratti E., Baralle M., Bralle F.E. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucl Acid Res 2006, 34:3494-3501.
45. Baralle M., Skoko N., Knezevich A., et al. NF1 mRNA biogenesis: effects of the genomic milieu in splicing regulation of the NF1 exon 37. FEBS Lett 2006, 580:4449-4456.
46. Skoko N., Baralle M., Buratti E., Baralle F.E. The pathological splicing mutation c.6792C>G in NF1 exon 37 causes a change in tenancy between antagonistic splicing factors. FEBS Lett 2008, 582:2231-2236.
47. Nilsen T.W., Graveley B.R. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463:457-463.
48. Chakarova C.F., Hims M.M., Bolz H., et al. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet 2002, 11:87-92.
49. Mordes D., Lou X., Kar A., et al. Pre-mRNA splicing and retinitis pigmentosa. Mol Vis 2006, 12:1259-1271.
50. Zhang Z., Lotti F., Dittmar K., et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008, 133:585-600.
51. Troadec M.B., Warner D., Wallace J., et al. Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria. Blood 2011, 117:5494-5502.